Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D 2 receptor long isoform mRNA levels

European Journal of Endocrinology

Volumn 166, Issue 3, 2012, Pages 383-390

  Shimazu, Satoko ^a,b   Shimatsu, Akira ^b   Yamada, Shozo ^c   Inoshita, Naoko ^c   Nagamura, Yuko ^a   Usui, Takeshi ^b   Tsukada, Toshihiko ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P53;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOPAMINE 2 RECEPTOR GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTINOMA; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; PROMOTER REGIONS, GENETIC; RECEPTORS, DOPAMINE D2; RNA ISOFORMS; RNA, MESSENGER; YOUNG ADULT;

EID: 84857955810     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0656     Document Type: Article

References (41)

1. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005 8 43-52. (doi:10.1007/s11102-005-5085-2)
2. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
3. Breidahl HD, Topliss DJ & Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. BMJ 1983 287 451-452. (doi:10.1136/bmj.287.6390.451)
4. McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B &Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinemia associate with transition from micro to macroadenoma. Clinical Endocrinology 2007 66 149-150. (doi:10.1111/j.1365-2265.2006.02686.x)
5. Behan LA, Draman MS, Moran C, King T, Crowley RK, O'Sullivan EP, Smith D, Thompson CJ & Agha A. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 2011 14 362-366. (doi:10.1007/s11102-009-0168-0)
6. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AM, Ballarino C, Stalldecker G & Becu-Villalobos D. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocrine Pathology 2009 20 35-40. (doi:10.1007/s12022-009-9057-3)
7. Alberiche Ruano M, Boronat Cortés M, Ojeda Pino A, Rodriguez Perez C, Gracía Nuñez M, Marrero Arencibia D & Novoa Mogollón FJ. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma. Pituitary 2010 13 380-382. (doi:10.1007/s11102-010- 0237-4)
8. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A. Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 500-509. (doi:10.1210/jcem-69-3-500)
9. 2 receptor: two molecular forms generated by alternative splicing. EMBO Journal 1989 8 4025-4034.
10. 2receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology 1991 129 1101-1103. (doi:10.1210/endo-129-2-1101)
11. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994 60 314-322. (doi:10.1159/000126764)
12. Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, Lin C, Zeng YJ & Zhuge QC. Expression of D2RmRNA isoforms and ER mRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. Journal of Neuro-oncology 2010 99 25-32. (doi:10.1007/s11060-009-0107- y)
13. Shimazu S, Shimatsu A, Usui T, Yamada S, Sato K, Tagami T, Naruse M & Inoshita N. Prolactin secreting pituitary atypical adenoma: cyber-knife radiosurgery-induced tumor shrinkage and normalization of PRL level. The 91st Annual Meeting of the Endocrine Society, Washington, DC 2009 June 12 (P3-654).
14. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F &Maira G. Ki-67 labeling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. Journal of Clinical Pathology 1999 52 107-111. (doi:10.1136/jcp.52.2.107)
15. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D & Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996 38 99-106. (doi:10.1097/00006123-199601000-00024)
16. DeLellis RA, Lloyd RV, Heitz PU & Eng C. Tumours of the pituitary. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs, pp 10-47. Lyon: IARC Press, 2004.
17. Popendikyte V, Laurinavicius A, Paterson AD, Macciardi F, Kennedy JL & Petronis A. DNA methylation at the putative promoter region of the human dopamine D2 receptor gene. NeuroReport 1999 10 1249-1255. (doi:10.1097/00001756- 199904260-00018)
18. 2-receptor levels and their expression in the stratum of Parkinsonian-monkeys. Progress in Neuropsychopharmacology and Biological Psychiatry 2000 24 607-617. (doi:10.1016/S0278-5846(00)00096-8)
19. Delgrange E, Daems T, Verhelst J, Abs R & Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology 2009 160 747-752. (doi:10.1530/EJE-09-0012)
20. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G & Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261. (doi:10.1210/jc.86.11.5256)
21. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A & Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European Journal of Endocrinology 2008 158 595-603. (doi:10.1530/EJE-07-0806)
22. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T & Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. Journal of Clinical Endocrinology and Metabolism 2008 93 4721-4727. (doi:10.1210/jc.2007-2758)
23. Passos VQ, Fortes MA, Giannella-Neto D & Bronstein MD. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 2009 89 163-170. (doi:10.1159/000156116)
24. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R &Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. Journal of Neurosurgery 1995 82 886-890. (doi:10.3171/jns.1995.82. 5.0886)
25. 2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 398-401. (doi:10.1210/jc.85.1.398)
26. 2 receptors using solution hybridization. Neurochemistry International 1992 20 (Suppl) 189S-195S. (doi:10.1016/0197-0186(92)90237-L)
27. 2receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1368-1375. (doi:10.1210/jc.83.4.1368)
28. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD & Gadelha MR. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 1931-1937. (doi:10.1210/jc.2008-1826)
29. 2dopamine receptor messenger ribonucleic acid is modulated by activated sex steroid receptors in the MMQ prolactin cell line. Endocrinology 1998 139 4213-4221. (doi:10.1210/en.139.10.4213)
30. i alpha proteins. Journal of Biological Chemistry 1994 269 23120-23127.
31. i coupling specificity. Journal of Biological Chemistry 2004 279 1601-1606. (doi:10.1074/jbc.M309792200)
32. B subtypes in a heterologous cell line. Molecular Endocrinology 1992 6 920-926. (doi:10.1210/me.6.6.920)
33. 2 receptors and G-proteins. Molecular Endocrinology 1993 7 161-170. (doi:10.1210/me.7.2.161)
34. Barlier A, Pellegrini-Bouiller I, Caccavelli L, Gunz G, Morange-Ramos I, Jaquet P & Enjalbert A. Abnormal transduction mechanisms in pituitary adenomas. Hormone Research 1997 47 227-234. (doi:10.1159/000185468)
35. 2 receptors and ERKs. PNAS 2002 99 14530-14535. (doi:10.1073/pnas.222319599)
36. 2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001 14 329-336. (doi:10.1385/ENDO:14:3: 329)
37. Winkelmann J, Pagotto U, Theodoropoulou M, Tatsch K, Saeger W, Müller A, Arzberger T, Schaaf L, Schumann EM, Trenkwalder C & Stalla GK. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. European Journal of Endocrinology 2002 146 81-88. (doi:10.1530/eje.0. 1460081)
38. 2receptors in human pituitary adenomas. Folia Histochemica et Cytobiologica 2010 48 394-397. (doi:10.2478/v10042-010-0031-1)
39. Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN & Farrell WE. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology 2011 152 364-373. (doi:10.1210/en.2010-0886)
40. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y & Melmed S. Heregulin regulates prolactinoma gene expression. Cancer Research 2009 69 4209-4216. (doi:10.1158/0008-5472.CAN-08-4934)
41. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF & Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. Journal of Clinical Endocrinology and Metabolism 1997 82 2962-2965. (doi:10.1210/jc.82.9. 2962)